{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T21:54:11Z","timestamp":1791410051282,"version":"4.3.3"},"reference-count":78,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,1,8]],"date-time":"2024-01-08T00:00:00Z","timestamp":1704672000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,1,8]],"date-time":"2024-01-08T00:00:00Z","timestamp":1704672000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007013","name":"F. Hoffmann-La Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007013","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Ther"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1007\/s40120-023-00570-w","type":"journal-article","created":{"date-parts":[[2024,1,8]],"date-time":"2024-01-08T08:02:21Z","timestamp":1704700941000},"page":"183-219","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["The Clinical Development of Taldefgrobep Alfa: An Anti-Myostatin Adnectin for the Treatment of Duchenne Muscular Dystrophy"],"prefix":"10.1007","volume":"13","author":[{"given":"Francesco","family":"Muntoni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barry J.","family":"Byrne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hugh J.","family":"McMillan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monique M.","family":"Ryan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brenda L.","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juergen","family":"Dukart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amita","family":"Bansal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valerie","family":"Cosson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roxana","family":"Dreghici","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maitea","family":"Guridi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Rabbia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah","family":"Staunton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giridhar S.","family":"Tirucherai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karl","family":"Yen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiling","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn R.","family":"Wagner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"the Taldefgrobep Alfa Study Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irvith","family":"Carvajal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anjaneya","family":"Chimalakonda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jochem","family":"Gokemeijer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Gulianello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Hellbach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Kozhich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Kukral","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harold","family":"Malone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr","given":"Jere E.","family":"Meredith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathew","family":"Pletcher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ginger","family":"Rakestraw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lumelle","family":"Schneeweis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna","family":"Swain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Zambito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lora","family":"Hamuro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jon E.","family":"Peterson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Hocknell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen","family":"Lou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malavi","family":"Madireddi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathew","family":"Pletcher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clifford M.","family":"Bechtold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael K.","family":"Ahlijanian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lora","family":"Hamuro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leslie K.","family":"Jacobsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Kozhich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jon E.","family":"Peterson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Zambito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heidemarie","family":"Kletzl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto L.","family":"Dubrovsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lilia","family":"Mesa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando","family":"Chloca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agustin","family":"Jauregu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristi","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monique","family":"Ryan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig","family":"Campbell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean","family":"Mah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Ho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Chiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanessa","family":"D\u2019Souza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raymy","family":"Sadowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Dao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michaela","family":"Grice","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiffany","family":"Price","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hugh","family":"McMillan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erick","family":"Sell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"McCormick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa","family":"Gidaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Seferian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yann","family":"P\u00e9r\u00e9on","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Armelle","family":"Magot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carole","family":"Vuillerot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrike","family":"Schara-Schmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valerie","family":"Sansone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilio","family":"Albamonte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Di Bari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jasmine","family":"Refran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Salmin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Vita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gian Luca","family":"Vita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Consulo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirofumi","family":"Komaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihiko","family":"Ishiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsuyoshi","family":"Matsumura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshio","family":"Saito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kana","family":"Ichihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Hayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kouji","family":"Terada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Takehara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuko","family":"Hayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhiro","family":"Takeshima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andres","family":"Nascimiento","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Natera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Carrera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesica","family":"Exposito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Ortez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julita","family":"Medina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Obdulia","family":"Moya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Roca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alicia","family":"Rodriguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Valle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Imelda J. M.","family":"de Groot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik H.","family":"Niks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marjolein J.","family":"van Heur-Neuman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Menno","family":"van der Holst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariacristina","family":"Scoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Brusa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abidha","family":"Afazal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eveline","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barry J.","family":"Byrne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Cripe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard S.","family":"Finkel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Heydemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"Matthews","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chandra","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katie","family":"Laubsher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shelley","family":"Mockeler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han","family":"Phan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kumaraswamy","family":"Sivakumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristy","family":"Osgood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Statland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cuixia","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn R.","family":"Wagner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Doris","family":"Leung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Genila","family":"Bibat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikia","family":"Stinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Servais","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugenio","family":"Mercuri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tina","family":"Duong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariacristina","family":"Scoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig","family":"Campbell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Strijbos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaas","family":"Veenstra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,1,8]]},"reference":[{"key":"570_CR1","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/s13023-017-0631-3","volume":"12","author":"S Ryder","year":"2017","unstructured":"Ryder S, Leadley RM, Armstrong N, et al. The burden, epidemiology, costs and treatment for Duchenne muscular dystrophy: an evidence review. Orphanet J Rare Dis. 2017;12:79.","journal-title":"Orphanet J Rare Dis"},{"key":"570_CR2","first-page":"1","volume":"2020","author":"S Han","year":"2020","unstructured":"Han S, Xu H, Zheng J, et al. Population-wide duchenne muscular dystrophy carrier detection by CK and molecular testing. BioMed Res Int. 2020;2020:1\u201312.","journal-title":"BioMed Res Int"},{"key":"570_CR3","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1136\/jmedgenet-2015-103387","volume":"53","author":"A Aartsma-Rus","year":"2016","unstructured":"Aartsma-Rus A, Ginjaar IB, Bushby K. The importance of genetic diagnosis for Duchenne muscular dystrophy. J Med Genet. 2016;53:145\u201351.","journal-title":"J Med Genet"},{"key":"570_CR4","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1186\/s13023-020-01430-8","volume":"15","author":"S Crisafulli","year":"2020","unstructured":"Crisafulli S, Sultana J, Fontana A, Salvo F, Messina S, Trifiro G. Global epidemiology of Duchenne muscular dystrophy: an updated systematic review and meta-analysis. Orphanet J Rare Dis. 2020;15:141.","journal-title":"Orphanet J Rare Dis"},{"key":"570_CR5","doi-asserted-by":"publisher","first-page":"18168","DOI":"10.3390\/molecules201018168","volume":"20","author":"MS Falzarano","year":"2015","unstructured":"Falzarano MS, Scotton C, Passarelli C, Ferlini A. Duchenne muscular dystrophy: from diagnosis to therapy. Molecules. 2015;20:18168\u201384.","journal-title":"Molecules"},{"key":"570_CR6","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.4045\/tidsskr.13.0836","volume":"134","author":"EJ Annexstad","year":"2014","unstructured":"Annexstad EJ, Lund-Petersen I, Rasmussen M. Duchenne muscular dystrophy. Tidsskr Nor Laegeforen. 2014;134:1361\u20134.","journal-title":"Tidsskr Nor Laegeforen"},{"key":"570_CR7","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1111\/j.1600-0854.2006.00519.x","volume":"8","author":"MJ Allikian","year":"2007","unstructured":"Allikian MJ, McNally EM. Processing and assembly of the dystrophin glycoprotein complex. Traffic. 2007;8:177\u201383.","journal-title":"Traffic"},{"key":"570_CR8","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1016\/j.nmd.2016.07.002","volume":"26","author":"P Bettica","year":"2016","unstructured":"Bettica P, Petrini S, D\u2019Oria V, et al. Histological effects of givinostat in boys with Duchenne muscular dystrophy. Neuromuscul Disord. 2016;26:643\u20139.","journal-title":"Neuromuscul Disord"},{"key":"570_CR9","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1212\/WNL.0000000000002337","volume":"86","author":"D Gloss","year":"2016","unstructured":"Gloss D, Moxley R III, Ashwal S, Oskoui M. Practice guideline update summary: corticosteroid treatment of Duchenne muscular dystrophy. Neurology. 2016;86:465\u201372.","journal-title":"Neurology"},{"key":"570_CR10","doi-asserted-by":"crossref","unstructured":"Matthews E, Brassington R, Kuntzer T, Jichi F, Manzur A. Corticosteroids for the treatment of Duchenne muscular dystrophy (Review). The Cochrane database of systematic reviews 2016:CD003725.","DOI":"10.1002\/14651858.CD003725.pub4"},{"key":"570_CR11","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1038\/mt.2011.59","volume":"19","author":"C Pichavant","year":"2011","unstructured":"Pichavant C, Aartsma-Rus A, Clemens PR, et al. Current status of pharmaceutical and genetic therapeutic approaches to treat DMD. Mol Ther. 2011;19:830\u201340.","journal-title":"Mol Ther"},{"key":"570_CR12","first-page":"129","volume":"32","author":"NG Laing","year":"2011","unstructured":"Laing NG, Davis MR, Bayley K, Fletcher S, Wilton SD. Molecular diagnosis of Duchenne muscular dystrophy: past, present and future in relation to implementing therapies. Clin Biochem Rev. 2011;32:129\u201334.","journal-title":"Clin Biochem Rev"},{"key":"570_CR13","doi-asserted-by":"publisher","first-page":"533","DOI":"10.2147\/DDDT.S97635","volume":"11","author":"KRQ Lim","year":"2017","unstructured":"Lim KRQ, Maruyama R, Yokota T. Eteplirsen in the treatment of Duchenne muscular dystrophy. Drug Des Dev Ther. 2017;11:533\u201345.","journal-title":"Drug Des Dev Ther"},{"key":"570_CR14","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1089\/nat.2017.0682","volume":"27","author":"A Aartsma-Rus","year":"2017","unstructured":"Aartsma-Rus A, Straub V, Hemmings R, et al. Development of exon skipping therapies for Duchenne muscular dystrophy: a critical review and a perspective on the outstanding issues. Nucleic Acid Ther. 2017;27:251\u20139.","journal-title":"Nucleic Acid Ther"},{"key":"570_CR15","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1358\/dot.2020.56.8.3159186","volume":"56","author":"S Anwar","year":"2020","unstructured":"Anwar S, Yokota T. Golodirsen for Duchenne muscular dystrophy. Drugs Today (Barc). 2020;56:491\u2013504.","journal-title":"Drugs Today (Barc)"},{"key":"570_CR16","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1001\/jamaneurol.2020.1264","volume":"77","author":"PR Clemens","year":"2020","unstructured":"Clemens PR, Rao VK, Connolly AM, et al. Safety, tolerability, and efficacy of viltolarsen in boys with duchenne muscular dystrophy amenable to exon 53 skipping: a phase\u00a02 randomized clinical trial. JAMA Neurol. 2020;77:982\u201391.","journal-title":"JAMA Neurol"},{"key":"570_CR17","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1002\/mus.27347","volume":"64","author":"KR Wagner","year":"2021","unstructured":"Wagner KR, Kuntz NL, Koenig E, et al. Safety, tolerability, and pharmacokinetics of casimersen in patients with Duchenne muscular dystrophy amenable to exon 45 skipping: a randomized, double-blind, placebo-controlled, dose-titration trial. Muscle Nerve. 2021;64:285\u201392.","journal-title":"Muscle Nerve"},{"key":"570_CR18","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1002\/humu.22758","volume":"36","author":"CL Bladen","year":"2015","unstructured":"Bladen CL, Salgado D, Monges S, et al. The TREAT-NMD DMD Global Database: analysis of more than 7,000 Duchenne muscular dystrophy mutations. Hum Mutat. 2015;36:395\u2013402.","journal-title":"Hum Mutat"},{"key":"570_CR19","unstructured":"US Food and Drug Administration. ELEVIDYS\u2122 Highlights of prescribing information. 2023. https:\/\/www.fda.gov\/media\/169679\/download. Accessed July 2023."},{"key":"570_CR20","unstructured":"Reference NGH. MSTN gene. 2019. https:\/\/ghr.nlm.nih.gov\/gene\/MSTN. Accessed July 2023."},{"key":"570_CR21","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1038\/387083a0","volume":"387","author":"AC McPherron","year":"1997","unstructured":"McPherron AC, Lawler AM, Lee SJ. Regulation of skeletal muscle mass in mice by a new TGF-beta superfamily member. Nature. 1997;387:83\u201390.","journal-title":"Nature"},{"key":"570_CR22","doi-asserted-by":"publisher","first-page":"12457","DOI":"10.1073\/pnas.94.23.12457","volume":"94","author":"AC McPherron","year":"1997","unstructured":"McPherron AC, Lee SJ. Double muscling in cattle due to mutations in the myostatin gene. Proc Natl Acad Sci USA. 1997;94:12457\u201361.","journal-title":"Proc Natl Acad Sci USA"},{"key":"570_CR23","doi-asserted-by":"publisher","first-page":"9306","DOI":"10.1073\/pnas.151270098","volume":"98","author":"S-J Lee","year":"2001","unstructured":"Lee S-J, McPherron AC. Regulation of myostatin activity and muscle growth. Proc Natl Acad Sci USA. 2001;98:9306\u201311.","journal-title":"Proc Natl Acad Sci USA"},{"key":"570_CR24","doi-asserted-by":"publisher","first-page":"15842","DOI":"10.1073\/pnas.2534946100","volume":"100","author":"NM Wolfman","year":"2003","unstructured":"Wolfman NM, McPherron AC, Pappano WN, et al. Activation of latent myostatin by the BMP-1\/tolloid family of metalloproteinases. Proc Natl Acad Sci. 2003;100:15842\u20136.","journal-title":"Proc Natl Acad Sci"},{"key":"570_CR25","first-page":"408","volume":"4","author":"K Hitachi","year":"2013","unstructured":"Hitachi K, Tsuchida K. Role of microRNAs in skeletal muscle hypertrophy. Front Physiol. 2013;4:408.","journal-title":"Front Physiol"},{"key":"570_CR26","doi-asserted-by":"publisher","first-page":"3140","DOI":"10.1210\/en.2006-1500","volume":"148","author":"AC Durieux","year":"2007","unstructured":"Durieux AC, Amirouche A, Banzet S, et al. Ectopic expression of myostatin induces atrophy of adult skeletal muscle by decreasing muscle gene expression. Endocrinology. 2007;148:3140\u20137.","journal-title":"Endocrinology"},{"key":"570_CR27","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1016\/j.jbiotec.2005.04.023","volume":"119","author":"J Acosta","year":"2005","unstructured":"Acosta J, Carpio Y, Borroto I, Gonz\u00e1lez O, Estrada MP. Myostatin gene silenced by RNAi show a zebrafish giant phenotype. J Biotechnol. 2005;119:324\u201331.","journal-title":"J Biotechnol"},{"key":"570_CR28","doi-asserted-by":"publisher","first-page":"2682","DOI":"10.1056\/NEJMoa040933","volume":"350","author":"M Schuelke","year":"2004","unstructured":"Schuelke M, Wagner KR, Stolz LE, et al. Myostatin mutation associated with gross muscle hypertrophy in a child. N Engl J Med. 2004;350:2682\u20138.","journal-title":"N Engl J Med"},{"key":"570_CR29","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1038\/nature01154","volume":"420","author":"S Bogdanovich","year":"2002","unstructured":"Bogdanovich S, Krag TO, Barton ER, et al. Functional improvement of dystrophic muscle by myostatin blockade. Nature. 2002;420:418\u201321.","journal-title":"Nature"},{"key":"570_CR30","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1002\/ana.10385","volume":"52","author":"KR Wagner","year":"2002","unstructured":"Wagner KR, McPherron AC, Winik N, Lee SJ. Loss of myostatin attenuates severity of muscular dystrophy in mdx mice. Ann Neurol. 2002;52:832\u20136.","journal-title":"Ann Neurol"},{"key":"570_CR31","doi-asserted-by":"publisher","first-page":"2160","DOI":"10.1038\/s41598-021-81669-8","volume":"11","author":"H Muramatsu","year":"2021","unstructured":"Muramatsu H, Kuramochi T, Katada H, et al. Novel myostatin-specific antibody enhances muscle strength in muscle disease models. Sci Rep. 2021;11:2160.","journal-title":"Sci Rep"},{"key":"570_CR32","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s13395-017-0141-y","volume":"7","author":"M St Andre","year":"2017","unstructured":"St Andre M, Johnson M, Bansal PN, et al. A mouse anti-myostatin antibody increases muscle mass and improves muscle strength and contractility in the mdx mouse model of Duchenne muscular dystrophy and its humanized equivalent, domagrozumab (PF-06252616), increases muscle volume in cynomolgus monkeys. Skelet Muscle. 2017;7:25.","journal-title":"Skelet Muscle"},{"key":"570_CR33","doi-asserted-by":"publisher","first-page":"2519","DOI":"10.1073\/pnas.0408729102","volume":"102","author":"KR Wagner","year":"2005","unstructured":"Wagner KR, Liu X, Chang X, Allen RE. Muscle regeneration in the prolonged absence of myostatin. Proc Natl Acad Sci USA. 2005;102:2519\u201324.","journal-title":"Proc Natl Acad Sci USA"},{"key":"570_CR34","first-page":"3957","volume":"125","author":"Z Bo Li","year":"2012","unstructured":"Bo Li Z, Zhang J, Wagner KR. Inhibition of myostatin reverses muscle fibrosis through apoptosis. J Cell Sci. 2012;125:3957\u201365.","journal-title":"J Cell Sci"},{"key":"570_CR35","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1208\/s12248-016-0006-z","volume":"19","author":"R Liu","year":"2017","unstructured":"Liu R, Hoffpauir B, Chilewski SD, et al. Accelerating regulated bioanalysis for biotherapeutics: case examples using a microfluidic ligand binding assay platform. AAPS J. 2017;19:82\u201391.","journal-title":"AAPS J"},{"key":"570_CR36","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1002\/jmri.21699","volume":"29","author":"V Positano","year":"2009","unstructured":"Positano V, Christiansen T, Santarelli MF, Ringgaard S, Landini L, Gastaldelli A. Accurate segmentation of subcutaneous and intermuscular adipose tissue from MR images of the thigh. J Magn Reson Imaging. 2009;29:677\u201384.","journal-title":"J Magn Reson Imaging"},{"key":"570_CR37","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1002\/pri.520","volume":"17","author":"E Scott","year":"2012","unstructured":"Scott E, Eagle M, Mayhew A, et al. Development of a functional assessment scale for ambulatory boys with Duchenne muscular dystrophy. Physiother Res Int. 2012;17:101\u20139.","journal-title":"Physiother Res Int"},{"key":"570_CR38","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1002\/mus.21212","volume":"39","author":"AJ Skalsky","year":"2009","unstructured":"Skalsky AJ, Han JJ, Abresch RT, Shin CS, McDonald CM. Assessment of regional body composition with dual-energy X-ray absorptiometry in Duchenne muscular dystrophy: correlation of regional lean mass and quantitative strength. Muscle Nerve. 2009;39:647\u201351.","journal-title":"Muscle Nerve"},{"key":"570_CR39","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.nmd.2017.10.003","volume":"28","author":"S Schmidt","year":"2018","unstructured":"Schmidt S, Hafner P, Klein A, et al. Timed function tests, motor function measure, and quantitative thigh muscle MRI in ambulant children with Duchenne muscular dystrophy: a cross-sectional analysis. Neuromuscul Disord. 2018;28:16\u201323.","journal-title":"Neuromuscul Disord"},{"key":"570_CR40","doi-asserted-by":"crossref","unstructured":"Wong B, Signorovitch J, Staunton H, et al. P.196 Estimating clinically meaningful change thresholds in the NORTH STAR ambolatory assessment (NSAA) and four-stair climb (4SC) in Duchenne muscular dystrophy (DMD). Neuromuscul Disord 2019;29:S106.","DOI":"10.1016\/j.nmd.2019.06.251"},{"key":"570_CR41","unstructured":"Muntoni F, Signorovitch J, Sajeev G, et al. Minimal detectable changes in functional measures in duchenne muscular dystrophy: a study of multiple centers, networks and trial arms. Presented at the Muscular Dystrophy Association Virtual Clinical & Scientific Conference, March 15\u201318, 2021"},{"key":"570_CR42","first-page":"62","volume":"5","author":"L Woodhouse","year":"2016","unstructured":"Woodhouse L, Gandhi R, Warden SJ, et al. A phase\u00a02 randomized study investigating the efficacy and safety of myostatin antibody LY2495655 versus placebo in patients undergoing elective total hip arthroplasty. J Frailty Aging. 2016;5:62\u201370.","journal-title":"J Frailty Aging"},{"key":"570_CR43","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1002\/ana.21338","volume":"63","author":"KR Wagner","year":"2008","unstructured":"Wagner KR, Fleckenstein JL, Amato AA, et al. A phase I\/IItrial of MYO-029 in adult subjects with muscular dystrophy. Ann Neurol. 2008;63:561\u201371.","journal-title":"Ann Neurol"},{"key":"570_CR44","unstructured":"Today MDN. Domagrozumab (PF-06252616). 2019. 10 July 2019. https:\/\/musculardystrophynews.com\/domagrozumab\/. Accessed July 2023."},{"key":"570_CR45","doi-asserted-by":"crossref","unstructured":"Place A, Barrett D, Nomikos G, et al. A phase\u00a02 study to evaluate the efficacy and safety of SRK-015 in patients with later-onset spinal muscular atrophy (TOPAZ): a study update (1963). Neurology. 2021;95:supplement.","DOI":"10.1212\/WNL.96.15_supplement.1963"},{"key":"570_CR46","doi-asserted-by":"publisher","first-page":"2239","DOI":"10.1212\/WNL.0000000000001070","volume":"83","author":"AA Amato","year":"2014","unstructured":"Amato AA, Sivakumar K, Goyal N, et al. Treatment of sporadic inclusion body myositis with bimagrumab. Neurology. 2014;83:2239\u201346.","journal-title":"Neurology"},{"key":"570_CR47","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1002\/mus.25268","volume":"55","author":"C Campbell","year":"2017","unstructured":"Campbell C, McMillan HJ, Mah JK, et al. Myostatin inhibitor ACE-031 treatment of ambulatory boys with Duchenne muscular dystrophy: results of a randomized, placebo-controlled clinical trial. Muscle Nerve. 2017;55:458\u201364.","journal-title":"Muscle Nerve"},{"key":"570_CR48","doi-asserted-by":"publisher","first-page":"185","DOI":"10.3233\/JND-150083","volume":"2","author":"SA Al-Zaidy","year":"2015","unstructured":"Al-Zaidy SA, Sahenk Z, Rodino-Klapac LR, Kaspar B, Mendell JR. Follistatin gene therapy improves ambulation in Becker muscular dystrophy. J Neuromuscul Dis. 2015;2:185\u201392.","journal-title":"J Neuromuscul Dis."},{"key":"570_CR49","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1016\/j.ymthe.2017.02.015","volume":"25","author":"JR Mendell","year":"2017","unstructured":"Mendell JR, Sahenk Z, Al-Zaidy S, et al. Follistatin gene therapy for sporadic inclusion body myositis improves functional outcomes. Mol Ther. 2017;25:870\u20139.","journal-title":"Mol Ther"},{"key":"570_CR50","first-page":"192","volume":"23","author":"JR Mendell","year":"2015","unstructured":"Mendell JR, Sahenk Z, Malik V, et al. A phase\u00a01\/2a follistatin gene therapy trial for becker muscular dystrophy. Mol Ther. 2015;23:192\u2013201.","journal-title":"Mol The"},{"key":"570_CR51","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1128\/MCB.01307-13","volume":"34","author":"E Lach-Trifilieff","year":"2014","unstructured":"Lach-Trifilieff E, Minetti GC, Sheppard K, et al. An antibody blocking activin type II receptors induces strong skeletal muscle hypertrophy and protects from atrophy. Mol Cell Biol. 2014;34:606\u201318.","journal-title":"Mol Cell Biol"},{"key":"570_CR52","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1093\/hmg\/ddy382","volume":"28","author":"KK Long","year":"2019","unstructured":"Long KK, O\u2019Shea KM, Khairallah RJ, et al. Specific inhibition of myostatin activation is beneficial in mouse models of SMA therapy. Hum Mol Genet. 2019;28:1076\u201389.","journal-title":"Hum Mol Genet"},{"key":"570_CR53","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s13395-018-0180-z","volume":"8","author":"A Iskenderian","year":"2018","unstructured":"Iskenderian A, Liu N, Deng Q, et al. Myostatin and activin blockade by engineered follistatin results in hypertrophy and improves dystrophic pathology in mdx mouse more than myostatin blockade alone. Skelet Muscle. 2018;8:34.","journal-title":"Skelet Muscle"},{"key":"570_CR54","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1016\/j.ympev.2015.09.025","volume":"94","author":"SM Dantas","year":"2016","unstructured":"Dantas SM, Weckstein JD, Bates JM, et al. Molecular systematics of the new world screech-owls (Megascops: Aves, Strigidae): biogeographic and taxonomic implications. Mol Phylogenet Evol. 2016;94:626\u201334.","journal-title":"Mol Phylogenet Evol"},{"key":"570_CR55","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1111\/cts.12420","volume":"9","author":"P Singh","year":"2016","unstructured":"Singh P, Rong H, Gordi T, Bosley J, Bhattacharya I. Translational pharmacokinetic\/pharmacodynamic analysis of MYO-029 antibody for muscular dystrophy. Clin Transl Sci. 2016;9:302\u201310.","journal-title":"Clin Transl Sci"},{"key":"570_CR56","doi-asserted-by":"publisher","first-page":"1661","DOI":"10.1158\/1535-7163.MCT-14-0681","volume":"14","author":"RC Smith","year":"2015","unstructured":"Smith RC, Cramer MS, Mitchell PJ, et al. Myostatin neutralization results in preservation of muscle mass and strength in preclinical models of tumor-induced muscle wasting. Mol Cancer Ther. 2015;14:1661\u201370.","journal-title":"Mol Cancer Ther"},{"issue":"109","key":"570_CR57","first-page":"635","volume":"2010","author":"SM Cadena","year":"1985","unstructured":"Cadena SM, Tomkinson KN, Monnell TE, et al. Administration of a soluble activin type IIB receptor promotes skeletal muscle growth independent of fiber type. J Appl Physiol. 1985;2010(109):635\u201342.","journal-title":"J Appl Physiol"},{"key":"570_CR58","unstructured":"Place A. Apitegromab, a novel high-affinity anti-promyostatin monoclonal antibdy for treating spinal muscular strophy: results of a phase\u00a02 interim analysis. Presented at MDA 2021 2021."},{"key":"570_CR59","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.nmd.2021.01.001","volume":"31","author":"KR Wagner","year":"2021","unstructured":"Wagner KR, Abdel-Hamid HZ, Mah JK, et al. Corrigendum to \u201cRandomized phase\u00a02 trial and open-label extension of domagrozumab in Duchenne muscular dystrophy\u201d [Neuromuscular Disorders, Vol. 30(6), 2020, pp. 492\u2013502]. Neuromuscul Disord. 2021;31:167\u20138.","journal-title":"Neuromuscul Disord"},{"key":"570_CR60","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1016\/j.nmd.2020.05.002","volume":"30","author":"KR Wagner","year":"2020","unstructured":"Wagner KR, Abdel-Hamid HZ, Mah JK, et al. Randomized phase\u00a02 trial and open-label extension of domagrozumab in Duchenne muscular dystrophy. Neuromuscul Disord. 2020;30:492\u2013502.","journal-title":"Neuromuscul Disord"},{"key":"570_CR61","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1016\/S1474-4422(19)30200-5","volume":"18","author":"MG Hanna","year":"2019","unstructured":"Hanna MG, Badrising UA, Benveniste O, et al. Safety and efficacy of intravenous bimagrumab in inclusion body myositis (RESILIENT): a randomised, double-blind, placebo-controlled phase\u00a02b trial. Lancet Neurol. 2019;18:834\u201344.","journal-title":"Lancet Neurol"},{"key":"570_CR62","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1242\/dmm.018424","volume":"8","author":"JW McGreevy","year":"2015","unstructured":"McGreevy JW, Hakim CH, McIntosh MA, Duan D. Animal models of Duchenne muscular dystrophy: from basic mechanisms to gene therapy. Dis Model Mech. 2015;8:195\u2013213.","journal-title":"Dis Model Mech"},{"key":"570_CR63","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1073\/pnas.81.4.1189","volume":"81","author":"G Bulfield","year":"1984","unstructured":"Bulfield G, Siller WG, Wight PA, Moore KJ. X chromosome-linked muscular dystrophy (mdx) in the mouse. Proc Natl Acad Sci USA. 1984;81:1189\u201392.","journal-title":"Proc Natl Acad Sci USA"},{"key":"570_CR64","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1038\/mt.2009.322","volume":"18","author":"J Dumonceaux","year":"2010","unstructured":"Dumonceaux J, Marie S, Beley C, et al. Combination of myostatin pathway interference and dystrophin rescue enhances tetanic and specific force in dystrophic mdx mice. Mol Ther. 2010;18:881\u20137.","journal-title":"Mol Ther"},{"key":"570_CR65","doi-asserted-by":"publisher","first-page":"3551","DOI":"10.1096\/fj.201600271RR","volume":"30","author":"N Bechir","year":"2016","unstructured":"Bechir N, Pecchi E, Vilmen C, et al. ActRIIB blockade increases force-generating capacity and preserves energy supply in exercising mdx mouse muscle in vivo. FASEB J. 2016;30:3551\u201362.","journal-title":"FASEB J"},{"key":"570_CR66","doi-asserted-by":"publisher","first-page":"15153","DOI":"10.1038\/ncomms15153","volume":"8","author":"E Latres","year":"2017","unstructured":"Latres E, Mastaitis J, Fury W, et al. Activin A more prominently regulates muscle mass in primates than does GDF8. Nat Commun. 2017;8:15153.","journal-title":"Nat Commun"},{"key":"570_CR67","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1007\/s00415-016-8379-6","volume":"264","author":"PM Burch","year":"2017","unstructured":"Burch PM, Pogoryelova O, Palandra J, et al. Reduced serum myostatin concentrations associated with genetic muscle disease progression. J Neurol. 2017;264:541\u201353.","journal-title":"J Neurol"},{"key":"570_CR68","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1097\/WCO.0000000000000853","volume":"33","author":"KR Wagner","year":"2020","unstructured":"Wagner KR. The elusive promise of myostatin inhibition for muscular dystrophy. Curr Opin Neurol. 2020;33:621\u20138.","journal-title":"Curr Opin Neurol"},{"key":"570_CR69","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1002\/cpdd.386","volume":"7","author":"I Bhattacharya","year":"2018","unstructured":"Bhattacharya I, Pawlak S, Marraffino S, et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of domagrozumab (PF-06252616), an antimyostatin monoclonal antibody, in healthy subjects. Clin Pharmacol Drug Dev. 2018;7:484\u201397.","journal-title":"Clin Pharmacol Drug Dev"},{"key":"570_CR70","doi-asserted-by":"publisher","first-page":"1859","DOI":"10.1038\/s41467-017-01486-4","volume":"8","author":"V Mariot","year":"2017","unstructured":"Mariot V, Joubert R, Hourde C, et al. Downregulation of myostatin pathway in neuromuscular diseases may explain challenges of anti-myostatin therapeutic approaches. Nat Commun. 2017;8:1859.","journal-title":"Nat Commun"},{"key":"570_CR71","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.133276","volume":"5","author":"DW Hammers","year":"2020","unstructured":"Hammers DW, Hart CC, Patsalos A, et al. Glucocorticoids counteract hypertrophic effects of myostatin inhibition in dystrophic muscle. JCI Insight. 2020;5:e133276.","journal-title":"JCI Insight"},{"key":"570_CR72","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1093\/protein\/gzq097","volume":"24","author":"D Lipovsek","year":"2011","unstructured":"Lipovsek D. Adnectins: engineered target-binding protein therapeutics. Protein Eng Des Sel. 2011;24:3\u20139.","journal-title":"Protein Eng Des Sel"},{"key":"570_CR73","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/j.jmb.2011.12.019","volume":"415","author":"A Koide","year":"2012","unstructured":"Koide A, Wojcik J, Gilbreth RN, Hoey RJ, Koide S. Teaching an old scaffold new tricks: monobodies constructed using alternative surfaces of the FN3 scaffold. J Mol Biol. 2012;415:393\u2013405.","journal-title":"J Mol Biol"},{"issue":"Suppl 3","key":"570_CR74","first-page":"S4","volume":"55","author":"D AlDeghaither","year":"2015","unstructured":"AlDeghaither D, Smaglo BG, Weiner LM. Beyond peptides and mAbs\u2013current status and future perspectives for biotherapeutics with novel constructs. J Clin Pharmacol. 2015;55(Suppl 3):S4-20.","journal-title":"J Clin Pharmacol"},{"key":"570_CR75","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1038\/mt.2015.88","volume":"23","author":"NB Lu-Nguyen","year":"2015","unstructured":"Lu-Nguyen NB, Jarmin SA, Saleh AF, Popplewell L, Gait MJ, Dickson G. Combination antisense treatment for destructive exon skipping of myostatin and open reading frame rescue of dystrophin in neonatal mdx mice. Mol Ther. 2015;23:1341\u20138.","journal-title":"Mol Ther"},{"key":"570_CR76","first-page":"3091","volume":"28","author":"N Lu-Nguyen","year":"2019","unstructured":"Lu-Nguyen N, Ferry A, Schnell FJ, et al. Functional muscle recovery following dystrophin and myostatin exon splice modulation in aged mdx mice. Hum Mol Genet. 2019;28:3091\u2013100.","journal-title":"Hum Mol Genet"},{"key":"570_CR77","doi-asserted-by":"crossref","unstructured":"Rybalka E, Timpani CA, Debruin DA, Bagaric RM, Campelj DG, Hayes A. The failed clinical story of myostatin inhibitors against Duchenne muscular dystrophy: exploring the biology behind the battle. Cells. 2020;9:2657.","DOI":"10.3390\/cells9122657"},{"key":"570_CR78","doi-asserted-by":"publisher","first-page":"1859","DOI":"10.1038\/s41467-017-01486-4","volume":"8","author":"V Mariot","year":"2017","unstructured":"Mariot V, Joubert R, Hourd\u00e9 C, et al. Downregulation of myostatin pathway in neuromuscular diseases may explain challenges of anti-myostatin therapeutic approaches. Nat Commun. 2017;8:1859.","journal-title":"Nat Commun"}],"container-title":["Neurology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-023-00570-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40120-023-00570-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-023-00570-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,13]],"date-time":"2024-01-13T10:09:53Z","timestamp":1705140593000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40120-023-00570-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,8]]},"references-count":78,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["570"],"URL":"https:\/\/doi.org\/10.1007\/s40120-023-00570-w","relation":{},"ISSN":["2193-8253","2193-6536"],"issn-type":[{"value":"2193-8253","type":"print"},{"value":"2193-6536","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,8]]},"assertion":[{"value":"11 September 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 November 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 January 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Francesco Muntoni was a site principal investigator in the trial and received support for the trial conduct. He has also received consultancy payments from F. Hoffmann-La Roche Ltd for participation in scientific advisory boards. Barry J. Byrne was a site principal investigator in the trial and received support for the trial conduct. Hugh J. McMillan was a site principal investigator in the trial and has received support for the trial conduct. He has also received consultancy payments from F. Hoffmann-La Roche Ltd for participation in scientific advisory boards. Monique M. Ryan was a site principal investigator in the trial and has received support for the trial conduct. Brenda L. Wong was a site principal investigator in the trial and received support for the trial conduct. Jurgen Dukart is a former employee of and received consultancy fees from F. Hoffmann\u2013La Roche Ltd. Amita Bansal is a former employee of F. Hoffmann-La Roche Ltd. New affiliation: Novartis International AG, Basel, Switzerland. Roxana Dreghici is a former employee and shareholder of F. Hoffmann-La Roche Ltd. New affiliation: Solid Biosciences Inc., Charlestown, MA, USA. Valerie Cosson is an employee and shareholder of Roche Products Ltd. Maitea Guridi is an employee and shareholder of F. Hoffmann-La Roche Ltd. Michael Rabbia is an employee and shareholder of Genentech, Inc, a member of the Roche Group. Hannah Staunton is an employee and shareholder of Roche Products Ltd. Giridhar S Tirucherai is a former employee and shareholder of Bristol Myers Squibb. New affiliation: Scholar Rock Inc., Cambridge, MA, USA. Karl Yen is a former employee and shareholder of F. Hoffmann-La Roche Ltd. New affiliation: Sanofi SA, Basel, Switzerland. Xiling Yuan is an employee and shareholder of Bristol Myers Squibb. Kathryn R. Wagner was a site principal investigator in the trial and received support for the trial conduct. She is a former employee of F. Hoffmann-La Roche Ltd. New affiliation: Novartis International AG, Basel, Switzerland.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The taldefgrobep alfa clinical trials were conducted in accordance with the principles of the 1964 Declaration of Helsinki\u00a0and its later amendments, and in accordance with Good Clinical Practice guidelines. Approval from the institutional review board\/independent ethics committee at each participating study site was obtained before each of the studies started and the studies were registered with ClinicalTrials.gov. Signed written informed consent was collected prior to study participation from participants, and, in the case of minors, from parents, guardians, or legally acceptable representatives.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}